Beranda › Skleroderma Difus › Pennsylvania › Philadelphia
Uji klinis Skleroderma Difus di Philadelphia, PA
4 studi untuk Skleroderma Difus mencari peserta di lokasi sekitar Philadelphia (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Menerima pesertaFase 2
- EncompaSSc site in Philadelphia, PA, Philadelphia
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Menerima pesertaFase 3
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Menerima pesertaFase 2/3
- GSK Investigational Site, Philadelphia
- GSK Investigational Site, Philadelphia
Platform Clinical Study for Conquering Scleroderma
Menerima pesertaFase 2
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
Uji klinis Skleroderma Difus di kota lain
- New York City, NY8 studi
- Chicago, IL7 studi
- Ann Arbor, MI7 studi
- Durham, NC6 studi
- Los Angeles, CA6 studi
- Baltimore, MD5 studi
- Houston, TX5 studi
- Boston, MA5 studi
- Pittsburgh, PA4 studi
- Kansas City, KS4 studi
- New Orleans, LA4 studi
- Aurora, CO3 studi
Studi lain di Philadelphia
- Kanker (semua jenis)59 studi
- Kanker Payudara56 studi
- Kanker Paru Non-Sel Kecil51 studi
- Kanker Metastatik46 studi
- Kanker Prostat44 studi
- Kanker Ovarium44 studi
- Kanker Kolorektal44 studi
- Kanker Paru36 studi
- Leukemia Mieloid Akut34 studi
- Gagal Jantung31 studi
- Kanker Endometrium28 studi
- Karsinoma Sel Skuamosa Kepala dan Leher26 studi
Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.